Search

Warfarin

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. … Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America.

Acetylene

Zuclopenthixol

Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. … Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.

Zinc gluconate

It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and with decreased symptom severity. … Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA [L2081].

Prednisolone acetate

[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]

Anifrolumab

erythematosus, but so far only anifrolumab has been approved. … [A237054] Anifrolumab has also been investigated for the treatment of Scleroderma.[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929]

Perflutren

The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. … a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas

Pyridostigmine

[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet.

Patent Blue

[A32574] It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. … Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979.[L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574]

Semaglutide

as the first approved drug for such use since 2014. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.